ExThera Gets Canadian Green Light for Blood Filter to Treat COVID-19
ExThera Medical’s Seraph 100 Microbind Affinity blood filter has received an interim order from the Canadian Health Authority permitting its use in relation to COVID-19.
The Martinez, Calif.-based company says the Seraph 100 can reduce bacterial, viral and fungal loads in the bloodstream and has been used on more than 500 U.S. and EU patients with COVID-19 since April 2020.
The device has Emergency Use Authorization from the FDA to treat COVID-19, and previously earned a CE mark in 2019 for the treatment of certain bloodstream infections, becoming the first CE-marked extracorporeal device to absorb pathogens from the blood.
A preliminary clinical study has shown the Seraph 100 can “dramatically reduce mortality” in severe COVID-19 cases, ExThera said.